Ly-1 B cells have the distinctive property of continuous self-replenishment and, as we have shown previously, can be further distinguished from conventional B cells on the basis of greatly elevated constitutive and inducible production of the recently described cytokine interleukin 10 (IL-10). To test the possibility that II--10 acts as either an autocrine or paracrine growth factor for Ly-1 B cells, we treated mice continuously from birth to 8 wk of age with a monoclonal rat IgM antibody that specifically neutralizes mouse IL-10. Mice treated in this way lacked peritonealresident Ly-1 B cells, contained greatly reduced serum immunoglobulin M levels, and were unable to generate significant in vivo antibody responses to intraperitoneal injections of od,3-dextran or phosphorylcholine, antigens for which specific B cells reside in the Ly-1 B cell subset. In contrast, conventional splenic B cells of anti-Ilcl0-treated mice were normal with respect to total numbers, phenotype, and in vitro responsiveness to B cell mitogens and the thymus-dependent antigen trinitrophenyl-keyhole limpet hemocyanin (TNP-KLH). The mechanism ofLy-1 B cell depletion appeared to be related to elevation of endogenous interferon 3' (IFN-3,) levels in anti-IL-10-treated mice, since coadministration of neutralizing anti-IFN-3' antibodies substantially restored the number of peritoneal-resident Ly-1 B cells in these mice. These results implicate Ibl0 as a regulator of Ly-1 B cell development, and identify a procedure to specifically deplete Ly-1 B cells, thereby allowing further evaluation of the role of these cells in the immune system. " [-1 B cells (1-5) comprise "~2% of the total B cells of an l.a adult mouse and exhibit several intriguing properties that distinguish them from conventional B cells: although barely detectable in most primary and secondary lymphoid tissues (6), they are greatly enriched in the peritoneal and pleural cavities, as are their progeny in gut-associated lymphoid tissue (7, 8); they develop and predominate in early ontogeny (7), and are then self-replenishing for the life of the animal (1, 9); they produce a restricted repertoire (10) of low-affinity antibodies that are highly cross-reactive with self-determinants (11), and do not appear to mature by somatic mutation (10, 12); they generate most of the IgM antibody found in serum (6, 9, 11), and produce the entire antibody response elicited by several bacterial determinants, such as phosphorylcholine and od,3-dextran (9, 13). Although their precise role in the immune system is unclear, the various models that have been advanced, based on the specificities of antibodies produced by Ly-1 B cells, include roles in antibacterial immunity (14, 15) , in clearance of host cellular debris such as senescent erythrocytes (16, 17) , and in modulation of the antibody repertoire during development (18-21). Our recent finding that Ly-1 B cells are potent producers of 23) , an immunosuppressive cytokine that downregulates production of several monokines (24, 25) and T cell-derived cytokines (26, 27) , raises the possibility of a broader immunoregulatory role of Ly-1 B cells. Many of these distinguishing features are difficult to evaluate in humans, but a population of Lyl-bearing human B lymphocytes with related properties has been identified (5, (28) (29) (30) (31) (32) . In this manuscript we test the possibility that constitutive Ibl0 production by Ly-1 B cells (22, 23) contributes either directly or indirectly to their demonstrated ability for self-replenishment.
"[-1 B cells (1-5) comprise "~2% of the total B cells of an l.a adult mouse and exhibit several intriguing properties that distinguish them from conventional B cells: although barely detectable in most primary and secondary lymphoid tissues (6) , they are greatly enriched in the peritoneal and pleural cavities, as are their progeny in gut-associated lymphoid tissue (7, 8) ; they develop and predominate in early ontogeny (7) , and are then self-replenishing for the life of the animal (1, 9); they produce a restricted repertoire (10) of low-affinity antibodies that are highly cross-reactive with self-determinants (11), and do not appear to mature by somatic mutation (10, 12) ; they generate most of the IgM antibody found in serum (6, 9, 11) , and produce the entire antibody response elicited by several bacterial determinants, such as phosphorylcholine and od,3-dextran (9, 13) . Although their precise role in the immune system is unclear, the various models that have been advanced, based on the specificities of antibodies produced by Ly-1 B cells, include roles in antibacterial immunity (14, 15) , in clearance of host cellular debris such as senescent erythrocytes (16, 17) , and in modulation of the antibody repertoire during development (18) (19) (20) (21) . Our recent finding that Ly-1 B cells are potent producers of IL-10 (22, 23) , an immunosuppressive cytokine that downregulates production of several monokines (24, 25) and T cell-derived cytokines (26, 27) , raises the possibility of a broader immunoregulatory role of Ly-1 B cells. Many of these distinguishing features are difficult to evaluate in humans, but a population of Lyl-bearing human B lymphocytes with related properties has been identified (5, (28) (29) (30) (31) (32) . In this manuscript we test the possibility that constitutive Ibl0 production by Ly-1 B cells (22, 23) contributes either directly or indirectly to their demonstrated ability for self-replenishment.
Materials and Methods
Mice. Mid-term pregnant BALB/c mice and C3H/HeJ mice were obtained from Simonsen Laboratory (Gilroy, CA).
Anti-ll_,lO Treatment. 5 Specific antibody responses against phosphorylcholine and c,l,3-dextran were determined after challenging anti-IL-10 or control mice intraperitoneally with 0.5 ml saline, 50/xg c*l,3-dextran derived from Leuconostoc raesentewides provided by Dr. Slodki (U.S.
Department of Agriculture Agricultural Research Service), or 2 x 10 s heat-killed Streptococcus pneuraoniae as a source of phosphorylcholine, as previously described (36, 37) . Sera were collected from all mice 7 d later, and analyzed for specific antibody to cd,3-dextran or phosphorykholine using ELISAs described in detail elsewhere (36, 37) . Specific antibody responses against TNP-KLH were determined after challenging mice intraperitoneally with 10 #g TNP-KLH, and collecting sera 7 d later for IgM analysis, and 10 and 14 d later for IgG analysis. TNP-specific antibodies were quantitated using an ELISA described in detail elsewhere (38) . In all cases, anti-Ibl0 treatment was continued between antigen challenge and sera collection.
Proliferation Assays. Pooled spleen cells at 2 x 106/ml obtained from three mice in each group were cultured for 3 d in medium alone, or medium supplemented with LPS (50 /~g/ml), goat anti-mouse-IgM antibodies (0611-0201; Cappel Laboratories, Cochranville, PA) (50/zg/ml), or hamster anti-mouse CD3 antibodies (a gift from Dr. J. Bluestone, University of Chicago, Chicago, IL) (5/~g/ml). For anti-CD3 stimulation, the antibody was coated onto the microtiter plate before addition of spleen cells. Proliferation was evaluated via incorporation of [3H]thymidine, after a 16-h pulse with 1/~Ci/well [3H]thymidine (NET 027; New England Nuclear, Boston, MA).
IFN-T ELISA. Serum samples collected from anti-IL-10-treated
or control mice were assayed for murine IFN-3~ using a cytokinespecific ELISA described in detail elsewhere (34, 35) .
R.esults
Continuous IblO Neutralization Depletes Mice of Ly-1 B Cells. Male and female BALB/c mice were injected three times per week from birth to 8 wk of age with graded doses of a neutralizing rat IgM anti-mouse IL-10 mAb designated SXC.1 (33) , and subsequently analyzed for Ly-1 B cell number and function. Control groups of age-matched BALB/c mice receiving no treatment or equivalent injections of either PBS or an irrelevant rat IgM isotype control (designated JS/D) were included for comparison. Antibodies were administered either intraperitoneally or subcutaneously without significant alteration of the outcome. The antibody injection regimen used yielded an average serum rat IgM level at 8 wk of 50 #g/ml as measured by a rat IgM-specific ELISA in the case of both SXC.1 and J5/D antibodies (data not shown). After the 8 wk of treatment, the anti-IL-10-treated mice were indistinguishable from the three control groups of mice in terms of the following criteria: total body weight, gross histological examination of liver, spleen, thymus, lymph nodes, intestines, and lungs; hematocrits; total numbers of white blood cells in spleen, thymus, lymph nodes, and peritoneum; and proportions of B cells, T cells, and non-B/-T cells in spleen, lymph nodes, and thymus (data not shown). In contrast, immunofluorescent phenotyping of cells obtained in the pooled peritoneal washes collected from the 5-10 mice comprising each of the four experimental groups described revealed a striking depletion of IgM + and IgD + cells in the anti-IL-10 (SXC.1)-treated mice, but not in any of the control animals ( Fig. 1 ). Identical data have been obtained in 24 independent experiments including two using C3H/HeJ mice, and several using a separate rat IgG1 anti-IL-10 neutralizing antibody. Anti-IL-10-treated animals were also depleted of B220-bearing peritoneal cells, as evaluated by immunofluorescence (data not shown), and of LPS-responsive peritoneal cells, as evaluated by the ability of these cells to incorporate [3H]-thymidine after 3 d of coculture with 50 gg/ml LPS (not shown). These findings suggest that anti-II:10-treated BALB/c mice contain no B cells in their peritoneal cavities, in contrast to the 1-5 x 106 B cells that can normally be recovered from this site. It is significant that we show elsewhere (23) by three-color immunofluorescence that the peritoneal cavities of 8-wk-old BALB/c mice in our animal facility contain very few (<5%) conventional B cells. The results shown in Fig. 1 therefore represent a depletion of Ly-1 B cells, predominantly. Despite this striking depletion of peritoneal B cells, the total cellularity of the peritoneal cavities of anti-IL-10-treated mice did not differ significantly from those of the control groups (data not shown). Further immunofluorescence analyses, together with differential hemopoietic cell counts, showed that the loss of B cells was compensated by an increase in peritoneal CD4 + T cells and granulocytes in ities to generate in vivo antibody responses to c~l,3-dextran or phosphorylcholine (36, 37) (Fig. 3) , two thymus-independent antigens for which functionally responsive B cells reside entirely within the Ly-1 B cell subset (9, 13) . to injection with the thymus-dependent antigen TNP-KLH (Fig. 5) . Secondary responses to TNP-KLH were also normal in anti-Ibl0-treated mice (data not shown). Second, splenic B cells from anti-Ibl0-treated mice developed normal in vitro proliferative responses to 50 #g/ml LPS or anti-IgM antibody (Table 1) . The background proliferative responses of spleen cells from anti-II_-10-treated mice were frequently threeto fivefold higher than that of controls, however, the significance and explanation for this is not yet clear (Table  1) . Collectively, these data suggest that conventional B ceils in anti-Ibl0-treated mice are quantitatively and functionally indistinguishable from those in control mice.
Mechanism of Ly-1 B Cell Depletion. Several possible mechanisms were considered as explanations for the depletion of Ly-1 B cells in anti-IL-10-treated mice. This effect did not appear to involve selective cytotoxicity of Ly-1 B cells by the anti-IL-10 antibodies, as injection of the same antibodies into adult mice had no effect on subsequent recoveries of total peritoneal wash cells (not shown), or total peritoneal B cells (Fig. 6) 1, 2, or 3 d later. As an alternative explanation, we considered the possibility that Ly-1 B cell depletion reflected a secondary consequence of some other endogenous cytokine perturbation. Indeed, anti-ID10-treated mice were generally found to have elevated serum IFN-3~ levels (Fig. 7) , an observation that was consistent with the previously reported ability of IL-10 to suppress IFN-'y production by Thl and NK cells in vitro (26, 27, 39) . To test the possibility that this anti-Ib 10-induced elevation of IFN-~/was either directly or indirectly responsible for depletion of Ly-1 B cells, mice were injected from birth to adulthood with a combination of anti-IL-10 and anti-IFN-~/-neutralizing antibodies, or anti-IL-10 and an appropriate isotype control antibody. The results showed that Experiment No. coadministration of anti-IFN-y antibodies (Fig. 8 ), but not its isotype control (data not shown), substantially reduced the ability of anti-Ibl0 treatment to deplete mice of peritoneal Ly-1 B cells. It is important to note that continued ad- * Animals were treated from birth to 8 wk of age as described in Fig.  1 . Pooled spleen cells at 2 x 106/ml obtained from three mice in each group were cultured for 3 d in medium alone, or medium supplemented with LPS (50 #g/ml), goat anti-mouse IgM antibodies (50/~g/ml), or hamster anti-mouse CD3 antibodies (5 #g/m1). For anti-CD3 stimulation, the antibody was coated onto the microtiter plate before addition of spleen cells. Proliferation was evaluated via incorporation of ministration of anti-IFN-3, antibodies alone, or the combination of anti-Ibl0 plus anti-IFN-T antibodies, did not alter the recovery of total peritoneal wash cells from mice treated with just anti-Ibl0 or its isotype control. We interpret these data as evidence in support of the concept that Ly-1 B cell depletion is at least in part a consequence of IFN-3' elevation in anti-IL-10-treated mice.
Discussion
The data outlined in this study indicate that continuous treatment of mice from birth to adulthood with anti-IL-10 antibodies drastically reduces total Ly-1 B cell number and function, without altering the number, phenotype, or immunocompetence of conventional B cells located in spleens of these same animals. Several observations support the pro- ! : 9 10 13 Experiment No.
Serum IFN-T levels in anti-Ibl0-treated or control mice. BALB/c mice were injected from birth until 8 wk with anti-lL-10 antibody (e) or an isotype control (O). Sera collected at 8 wk were analyzed for IFN-'y by immunoassay (34, 35) . The results show five separate experiments, with each circle representing an individual mouse.
posed depletion of Ly-1 B cells in anti-Ibl0-treated mice: (a) anti-Ibl0-treated mice contain few or no B cells in their peritoneal cavities, a site of Ly-1 B cell enrichment in normal mice. It is significant that we show elsewhere that peritoneal wash cells of 8-wk-old BALB/c mice in our animal facility contain fewer than 5% conventional B cells by phenotypic analysis (22, 23) ; (b) anti-ID10-treated mice contain 0-10% of normal serum IgM levels, which is consistent with previous reconstitution ~periments identifying Ly-1 B cells as the predominant source of circulating IgM (7, 9, and 11); and (c) anti-IL-10-treated mice generate little or no antibody in response to injection with phosphorylcholine and od,3-dextran, antigens for which specific B cells reside in the Ly-1 B cell subset (9, 13) . The data suggesting an unaltered conventional B cell compartment in anti-IL,10-treated mice are equally compeUing, with unchanged numbers of splenic B cells displaying normal cell surface marker phenotypes, and responding normally to a thymus-dependent antigen and B cell mitogens. The selective depletion of Ly-1 B cells in anti-IL-10-treated mice was found to be transient, as Ly-1 B cells reappeared in the peritoneal cavities of these animals several weeks after anti-IL,10 treatment was discontinued (H. Ishida, et al., manuscript in preparation).
Several possible mechanisms were considered as explanation for the selective depletion of Ly-1 B cells in anti-Ibl0-treated mice. The data presented indicate that this is at least partially the consequence of IFN-T elevation after anti-IL-10 treatment, since coadministration of neutralizing anti-II:10 and anti-IFN-3, antibodies substantially prevented the depletion of peritoneal B cells in these studies. The implication that IFN-T either directly or indirectly inhibits Ly-1 B cell development is reminiscent of our previous observations that IFN-3' causes slight suppression of Ib5 induced in vitro (24, 25) , it is likely that anti-Ibl0 treatment will lead to elevation of endogenous monokine levels. Indeed, we show elsewhere (H. Ishida et al., manuscript in preparation) that anti-IL-10-treated mice are ~,50-fold more susceptible to death by LPS-induced shock, an event that is known to be mediated by monokines (41) (42) (43) (44) , and that 5 of 32 individual anti-IL-10-treated mice contained substantial levels of serum II,-6, a monokine that is generally not found in the circulation of normal animals and that could not be detected in the sera of any of 10 control mice from these experiments. On this point however, it is worth considering that II~6 transgenic mice or animals with greatly elevated serum monokine levels resulting from in vivo administration of LPS appear to have normal serum IgM levels (45, 46) , suggesting unchanged numbers of Ly-1 B cells. Our initial premise that II~10 acts as an autocrine growth factor for Ly-1 B cells but not conventional B cells, a notion derived from our previous findings that Ly-1 B cells, but not conventional B cells generate constitutive and inducible I1,-10 (22, 23), now seems unlikely in light of the substantial numbers of peritoneal Ly-1 B cells recovered from mice treated with both anti-IL-10 and anti-IFN-'y antibodies. The Ly-1 B cell-depleted mouse we have created by continuous anti-Ibl0 treatment bears considerable similarity to the previously described immunodeficient xid mouse, a spontaneous mutant strain derived from CBA/CaH mice which lacks Ly-1 B cells, and is unresponsive to a subset of thymusindependent antigens (7, 47) . Despite these similarities, our preliminary investigations have revealed that xid mice produce Ibl0 normally, and contain functional Ibl0 receptors (N. Go and M. Howard, manuscript in preparation), thus distinguishing x/d mice and anti-Ibl0-treated mice mechanistically. Furthermore, one property that distinguishes anti-IL-10-treated mice from xid mice is the in vitro responsiveness of spleen cells to anti-IgM stimulation, exhibited by the former (Table 1) , but not the latter animals (48) . Further efforts to characterize the responsiveness of anti-Ibl0-treated mice to the variety of thymus-independent type II antigens and microorganisms that are not recognized by xid mice are in progress. Whatever the relationship between xid mice and anti-IL-10-treated mice, it is hoped that the latter procedure will allow us to generate Ly-1 B cell-depleted mice of any haplotype, thereby allowing us to explore the role of this numerically small population of B cells within the context of the various genetic restrictions that underlie responsiveness to different antigens and microorganisms.
